Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ABNG vs VVOS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ABNG Captures Overall Composite Edge (53.0 HOLD vs 36.4 SELL), While VVOS Leads 4–1 on Growth & Valuation Pillars

ABNG Overall Winner 6-Pillar Tally: ABNG 1 – 4 VVOS (1 Tie) Matrix Metrics: ABNG 3 – 5 VVOS

As of Nov 20, 2026, ABNG (ABNG) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (53.0/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 3–5 (led by Options & Positioning), while VVOS wins 4–1 across the 6-pillar growth and valuation breakdown. ABNG trades at $20.21 (N/M Forward P/E, N/A operating margin) versus VVOS at $0.05 (N/M Forward P/E, -107.9% operating margin).

  • Growth vs. Quality Trade-Off: ABNG earns the overall head-to-head edge with a stronger Unified Composite Score (53.0/100 HOLD vs. VVOS 36.4/100 SELL) and 2.34β · 71% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: ABNG trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.3); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ABNG vs VVOS
ABNG US Equity Head-to-Head Winner
ABNG
Institutional Equity
$20.21
+8.39% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.34β · 71% Vol
Unified Composite Score
53.0 / 100 HOLD
Tech 55.0 Fund 56.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.8% over 20 days), RSI 61
RSI-14: 61.3 · SMA20: $18.56 · SMA50: $17.34
VVOS NASDAQ
Vivos Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.05
-5.1% 1D
Market Cap $1.9M
TTM Revenue $21M
Forward P/E N/M
Beta / 30D Vol 1.70β · 111% Vol
Unified Composite Score
36.4 / 100 SELL
Tech 25.0 Fund 35.0 Flow 50.0 Mom 30.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.8%), weak momentum, RSI 19
RSI-14: 18.9 · SMA20: $0.10 · SMA50: $0.13

6-Pillar Scorecard Institutional Category Breakdown (ABNG 1 – 4 VVOS)

Columns: Metric · ABNG · VVOS
1. Valuation Multiples VVOS
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 0.1x
2. Growth & Scale VVOS
Revenue Growth (YoY) N/A +34.9%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $21M
Market Cap N/A $1.9M
3. Profitability & Quality VVOS
Gross Margin N/A 61.9%
Operating Margin N/A -107.9%
Net Profit Margin N/A -121.8%
Return on Equity (ROE) N/A -8585.3%
4. Balance Sheet & Cash Flow VVOS
Cash Generation (TTM) N/A -$21M EBITDA
Cash Flow Margin N/A -99.3% EBITDA Mgn
Net Cash / Leverage N/A ROE -8585.3% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ABNG
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ABNG (3) vs VVOS (5)
Institutional Metric ABNG VVOS Criterion Row Edge
Market Capitalization
Scale
N/A $1.9M Larger Scale VVOS
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +34.9% Higher Growth VVOS
Operating Margin (TTM)
Profitability
N/A -107.9% Higher Margin VVOS
Net Profit Margin
Profitability
N/A -121.8% Higher Margin VVOS
Return on Equity (ROE)
Capital Efficiency
N/A -8585.3% Higher ROE VVOS
52-Week Range Position
Momentum
100% ($13–$20) 0% ($0–$3) Stronger Trend ABNG
Beta / 30D Volatility
Risk Regime
2.34β · 71% Vol 1.70β · 111% Vol Lower Realized Risk ABNG
Unified Institutional Score
Composite Signal
53.0 / 100 (HOLD) 36.4 / 100 (SELL) Higher Composite ABNG
Trailing 12M Revenue (USD)
Operating Scale
N/A $21M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 61.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 0.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$21M EBITDA (-8585.3% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ABNG +14.9 pp
ABNG: +8.73% · VVOS: -6.17%
3M Horizon ABNG +62.92 pp
ABNG: +11.58% · VVOS: -51.34%
6M Horizon ABNG +91.92 pp
ABNG: +16.63% · VVOS: -75.29%
1Y Horizon ABNG +135.45 pp
ABNG: +53.25% · VVOS: -82.2%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ABNG vs VVOS. Trailing 12-month operating profitability (ABNG N/A vs VVOS -107.9%) and valuation multiples (ABNG N/M vs VVOS N/M Forward P/E) are benchmarked directly in Pillar 4 below.

ABNG ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
VVOS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$21M
Gross Margin61.9%
Op. Margin-107.9%
ROE / Fwd P/E-8585.3% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ABNG UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ABNG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VVOS BREAKDOWN
113d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact VVOS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ABNG Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VVOS Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.9M market capitalization and -107.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ABNG vs VVOS Key Questions & Quantitative Answers

As of Nov 20, 2026, ABNG (ABNG) captures the overall head-to-head institutional edge over Vivos Therapeutics, Inc. (VVOS) on higher Unified Composite conviction (53.0/100 HOLD vs. 36.4/100 SELL) after splitting the core matrix 3–5 (led by Options & Positioning), while VVOS wins 4–1 across the 6-pillar growth and valuation breakdown. ABNG trades at $20.21 (N/M Forward P/E, N/A operating margin) versus VVOS at $0.05 (N/M Forward P/E, -107.9% operating margin). Growth vs. Quality Trade-Off: ABNG earns the overall head-to-head edge with a stronger Unified Composite Score (53.0/100 HOLD vs. VVOS 36.4/100 SELL) and 2.34β · 71% Vol risk profile, whereas VVOS leads top-line expansion (+34.9% YoY revenue growth, N/M PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: ABNG trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 61.3); meanwhile VVOS is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 18.9). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

VVOS leads the Growth & Scale pillar: ABNG posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with VVOS at +34.9% YoY revenue growth and +0.0% YoY earnings growth on $21M TTM revenue (61.9% gross margin, -107.9% operating margin). On trailing 12-month operating scale, ABNG generates N/A in USD-normalized revenue versus $21M for VVOS. In operating R&D and SG&A reinvestment, ABNG deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VVOS.

VVOS screens cheaper on headline valuation multiples. ABNG trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VVOS trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.1x EV/Revenue (-99.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ABNG (N/A ROE) versus VVOS (-8585.3% ROE) capital efficiency.

In options market volatility and institutional positioning, ABNG carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.34β · 71% Vol realized risk). By comparison, VVOS carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.70β · 111% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.